OS07.5 Interim analysis data from Phase 2 study on efficacy, safety & intratumoral pharmacokinetics of oral Selinexor (KPT-330) in patients with recurrent glioblastoma (GBM)

Background: The nuclear export protein exportin 1, (XPO1) is overexpressed in a wide variety of cancers. XPO1 overexpression in glioma correlates with higher grade and decreased overall survival. Selinexor (SEL) is an oral selective inhibitor of XPO1 which crosses the blood-brain barrier. SEL forces...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Lassman, A. B., Bent, M. J. V. D., Wen, P. Y., Walenkamp, A., Plotkin, S., Kung, A., Gardner, H., Shacham, S., Chudnovsky, A., Mau-Sorensen, P. M.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
ORAL PRESENTATIONS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463646/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.046
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars